A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I

PHASE3TerminatedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

July 8, 2020

Primary Completion Date

December 7, 2021

Study Completion Date

December 7, 2021

Conditions

Neurofibromatosis

Interventions

DRUG

NPC-12G gel

NPC-12G gel is containing 0.2% Sirolimus

Trial Locations (4)

Osaka University Hospital, Suita-shi

Jikei University Hospital, Minato-ku

Fukuoka University Hospital, Fukuoka

Tottori University Hospital, Tottori